Antoine Adenis

24.3k total citations · 5 hit papers
213 papers, 14.2k citations indexed

About

Antoine Adenis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Antoine Adenis has authored 213 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 121 papers in Pulmonary and Respiratory Medicine and 73 papers in Surgery. Recurrent topics in Antoine Adenis's work include Colorectal Cancer Treatments and Studies (79 papers), Gastric Cancer Management and Outcomes (68 papers) and Cancer Treatment and Pharmacology (55 papers). Antoine Adenis is often cited by papers focused on Colorectal Cancer Treatments and Studies (79 papers), Gastric Cancer Management and Outcomes (68 papers) and Cancer Treatment and Pharmacology (55 papers). Antoine Adenis collaborates with scholars based in France, United States and Japan. Antoine Adenis's co-authors include Olivier Bouché, Marc Ychou, Michel Ducreux, Thierry Conroy, Jaafar Bennouna, Jean‐Luc Raoul, S. Gourgou-Bourgade, Françoise Desseigne, Y. Bécouarn and Rosine Guimbaud and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Antoine Adenis

208 papers receiving 14.0k citations

Hit Papers

FOLFIRINOX versus Gemcitabine for Metastatic Pancr... 2000 2026 2008 2017 2011 2012 2000 2014 2022 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    2011 5.5k citations Marc Ychou, Olivier Bouché et al. profile →
  2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    2012 2.1k citations Marc Ychou, Olivier Bouché et al. profile →
  3. A phase II study
    2000 609 citations Antoine Adenis et al. European Journal of Cancer profile →
  4. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
    2014 276 citations Thierry Conroy, Marie‐Pierre Galais et al. The Lancet Oncology profile →
  5. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
    2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antoine Adenis France 40 10.4k 5.4k 4.0k 2.9k 2.2k 213 14.2k
Joon Oh Park South Korea 54 9.2k 0.9× 7.6k 1.4× 4.3k 1.1× 2.9k 1.0× 4.5k 2.0× 387 16.2k
Jean‐Baptiste Bachet France 39 11.4k 1.1× 4.2k 0.8× 2.7k 0.7× 4.1k 1.4× 2.5k 1.1× 213 13.5k
Jean‐Luc Van Laethem Belgium 44 7.9k 0.8× 3.2k 0.6× 3.4k 0.8× 2.2k 0.7× 1.4k 0.6× 275 10.4k
Christophe Louvet France 54 14.9k 1.4× 6.1k 1.1× 4.2k 1.1× 2.5k 0.8× 1.9k 0.9× 278 17.8k
Jeeyun Lee South Korea 58 7.6k 0.7× 6.7k 1.3× 3.1k 0.8× 2.9k 1.0× 3.4k 1.6× 506 14.4k
Ho Yeong Lim South Korea 58 6.6k 0.6× 5.7k 1.1× 3.6k 0.9× 2.6k 0.9× 3.5k 1.6× 369 15.0k
Rosine Guimbaud France 34 7.7k 0.7× 2.5k 0.5× 2.3k 0.6× 2.4k 0.8× 1.5k 0.7× 178 9.5k
Kenichi Sugihara Japan 72 10.9k 1.0× 6.8k 1.3× 7.7k 1.9× 1.6k 0.6× 2.6k 1.2× 508 17.6k
Milind Javle United States 57 7.4k 0.7× 3.9k 0.7× 6.2k 1.6× 2.3k 0.8× 3.1k 1.4× 399 11.9k
Pascal Hammel France 65 12.1k 1.2× 3.6k 0.7× 5.7k 1.4× 2.9k 1.0× 1.8k 0.8× 367 15.8k

Countries citing papers authored by Antoine Adenis

Since Specialization
Citations

This map shows the geographic impact of Antoine Adenis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antoine Adenis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antoine Adenis more than expected).

Fields of papers citing papers by Antoine Adenis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antoine Adenis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antoine Adenis. The network helps show where Antoine Adenis may publish in the future.

Co-authorship network of co-authors of Antoine Adenis

This figure shows the co-authorship network connecting the top 25 collaborators of Antoine Adenis. A scholar is included among the top collaborators of Antoine Adenis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antoine Adenis. Antoine Adenis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
May, Anne M., Antoine Adenis, Andreia Capela, et al.. (2025). Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study. European Journal of Cancer. 218. 115278–115278. 1 indexed citations
2.
Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721. 2 indexed citations
3.
4.
Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 94(3). 443–452. 1 indexed citations
5.
Adenis, Antoine, Guillaume Piessen, Samuel Le Sourd, et al.. (2023). Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.. Journal of Clinical Oncology. 41(4_suppl). 370–370.
6.
André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →
7.
Cousin, Sophie, Jean Philippe Metges, Carine Bellera, et al.. (2022). REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort.. Journal of Clinical Oncology. 40(16_suppl). 4060–4060. 2 indexed citations
8.
Cousin, Sophie, Coralie Cantarel, Jean‐Philippe Guégan, et al.. (2021). Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clinical Cancer Research. 27(8). 2139–2147. 95 indexed citations
9.
Shah, Manish A., Jaafar Bennouna, Toshihiko Doi, et al.. (2021). KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma. Future Oncology. 17(10). 1143–1153. 78 indexed citations
10.
11.
12.
Adenis, Antoine, et al.. (2020). Le protocole FLOT est-il le nouveau standard de chimiothérapie péri-opératoire des cancers de l’estomac ?. Bulletin du Cancer. 107(1). 54–60. 4 indexed citations
13.
Metges, Jean‐Philippe, Éric François, Manish A. Shah, et al.. (2019). The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Annals of Oncology. 30. iv130–iv130. 24 indexed citations
14.
15.
Mollévi, Caroline, Sophie Gourgou, Marie‐Pierre Galais, et al.. (2017). Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer. European Journal of Cancer. 84. 239–249. 14 indexed citations
16.
Conroy, Thierry, Marie‐Pierre Galais, Jean‐Luc Raoul, et al.. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. The Lancet Oncology. 15(3). 305–314. 276 indexed citations breakdown →
17.
Bertucci, François, Jean‐Yves Blay, I. L. Ray-Coquard, et al.. (2011). Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. Journal of Clinical Oncology. 29(15_suppl). e20506–e20506. 2 indexed citations
18.
Biron, Pierre, Elena Fumagalli, Aurore Blesius, et al.. (2010). Outcome of patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. A study performed with the EORTC Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology. 28. 2 indexed citations
19.
Adenis, Antoine, et al.. (1996). Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.. PubMed. 16(4A). 2063–7. 2 indexed citations
20.
Bonneterre, Jacques, et al.. (1993). Bromocriptin (B) and lanreotide (L) in advanced breast cancer: A phase II study. European Journal of Cancer. 29. S84–S84. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joon Oh Park Breakdown of academic impact, for papers by Jean‐Baptiste Bachet Breakdown of academic impact, for papers by Jean‐Luc Van Laethem Breakdown of academic impact, for papers by Christophe Louvet Breakdown of academic impact, for papers by Jeeyun Lee Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Rosine Guimbaud Breakdown of academic impact, for papers by Kenichi Sugihara Breakdown of academic impact, for papers by Milind Javle Breakdown of academic impact, for papers by Pascal Hammel
Rankless by CCL
2026